Loading
Regulators are unsure what to accept as proof that an anti-wasting drug helps. Agreeing on a simple measure such as stair climbing would unblock the whole field.
Cachexia drug development has repeatedly stalled on endpoint uncertainty: weight is easy but not clearly meaningful, and composite quality-of-life measures are noisy. Candidate function measures (stair climb power, six-minute walk, handgrip strength, wearable-derived daily step count) are simple and reproducible but not formally qualified. A qualification programme with pre-competitive data pooling would create a defined path.
Shares Cachexia, toxicity and the limits of the patient, Geriatric assessment, Exercise & lifestyle oncology, Patients lack understanding, navigation and agency.
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.
Shares Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Exercise & lifestyle oncology.
Shares Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Trial design, endpoints and cost.
Shares Cachexia, toxicity and the limits of the patient, Geriatric assessment, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards, Exercise & lifestyle oncology.
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Geriatric assessment, Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards.
Shares Patients lack understanding, navigation and agency, Trial design, endpoints and cost.
Shares Patients lack understanding, navigation and agency, Trial design, endpoints and cost.